Quest Diagnostics Inc. hit a new 52-week high, surpassing its previous peak of $168.17, which the company achieved on February 11th.

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...